Abstract Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) is a protein that potently attenuates fibrinolysis. A considerable proportion of its variability levels is genetically determined. It has been associated with arterial and venous thrombosis. We conducted a Genome Wide Scan for genes affecting variation in plasma TAFI levels in 398 subjects from 21 extended Spanish families. The data were analyzed by a variance-component linkage method. A strong linkage signal was found on the long arm of Chromosome 13, near the DNA marker D13S156, where the structural gene encoding for TAFI is located. In addition, other new linkage signals were detected on chromosome regions 5p and 7q. More importantly, we performed another multipoint linkage analysis of functional TAFI conditioned on TAFI antigen levels. We detected a strong linkage signal on Chromosome 19 (LOD = 3.0, P = 0.0001) suggesting a novel QTL in this region involved in the specific functional activity of TAFI, regardless of the TAFI antigen levels. One notable aspect of this study is the identification of new QTLs that reveal a clearer picture of the genetic determinants responsible for variation in TAFI levels. Another is the replication of the linkage signal of the CPB2 gene, which confirms an important genetic determinant for TAFI antigen levels. These results strongly suggest an oligogenic mode of inheritance for TAFI, in which CPB2 gene accounts for a proportion of the variation of the phenotype together with other unknown genes that may represent potential risk factors for thrombotic disease.
Introduction
The maintenance of the equilibrium between blood coagulation and fibrinolysis is crucial for normal hemostasis. The thrombin-activatable fibrinolysis inhibitor (TAFI) (Bajzar et al. 1995 ) is an inhibitor of fibrinolysis. It represents a crucial link between the coagulation system and fibrinolysis. TAFI is also known as procarboxypeptidase U. It is a zymogen secreted by the liver, following activation by the complex thrombin-thrombomodulin. It attenuates fibrinolysis potently by removing the fibrin C-terminal lysine and arginine residues that are important to bind plasminogen (Bajzar et al. 1995; Bouma et al. 2001) .
The relevance of TAFI levels in venous and arterial thrombotic disease is not absolutely clear. Several studies have investigated the role of funcional (TAFIf) and antigen TAFI (TAFIag) levels in arterial and venous thrombosis. Unfortunately, some of them present contradictory results. Whereas some state that elevated TAFIag levels could be a risk factor for arterial and thrombotic disease (de Bruijne et al. 2007; Eichinger et al. 2004; Ladenvall et al. 2007; Montaner et al. 2003; Schroeder et al. 2002; van Tilburg et al. 2000) , others suggest a protective effect (Juhan-Vague et al. 2002; Juhan-Vague and Morange 2003) . Previous studies from our laboratory found no relation between TAFIag levels and coronary artery disease (CAD) or ischemic stroke (IS) although they suggested that TAFIf levels in plasma significantly increased the risk of ischemic stroke about sixfold, and the risk of acute CAD almost fourfold (Santamaria et al. 2003 (Santamaria et al. , 2004 . Thus, the role of TAFI as a risk factor for cardiovascular disease is still unclear.
Given the considerable variation of TAFI plasma levels within populations, exploring the genetic determinants of this variation is important to clearly elucidate the role of TAFI as a risk factor for cardiovascular disease. Some studies have demonstrated that a significant proportion of the variation in TAFI plasma levels is genetic. Twin studies in different European populations estimated TAFI heritabilities ranging from 71 to 82% (Ariens et al. 2002; Bladbjerg et al. 2006; Peetz et al. 2004) . Also, a recent study of extended Mexican Americans families estimated the additive genetic heritability of TAFI levels as 53% (Warren et al. 2006 ) and found significant evidence of a Quantitative Trait Locus (QTL) located near the locus of the gene coding for TAFI (CPB2).
The gene encoding TAFI in humans (CPB2, MIM 603101) has 11 exons and measures 48 Kb. It is localized on Chromosome 13q14.11 (Boffa et al. 1999; Tsai and Drayna 1992; Vanhoof et al. 1996) . Different polymorphisms in this gene have been described and some of them have been associated with TAFI levels and with the risk of arterial and venous thrombotic disease (Boffa et al. 2008; Brouwers et al. 2001; de Bruijne et al. 2007; Franco et al. 2001; Henry et al. 2001; Juhan-Vague et al. 2002) . Nevertheless, the results in different populations are contradictory (Morange et al. 2005) suggesting that the genetic determinants of TAFI levels are still largely unknown. In addition (Tregouet et al. 2001 ) used a combined segregation-linkage analysis and provided evidence for two TAFI-linked QTLs still undetermined that explained 78% of the TAFI variation. Also, evidence for linkage apart from the structural gene have been obtained from a whole genome scan (Warren et al. 2006 ) meaning that other potential candidate genes influencing TAFI levels have yet to be identified.
Here we present a Genome Wide Scan linkage analysis performed in a Spanish population. To our knowledge, ours is the first study to describe the genetic factors that influence either TAFIf and TAFIag levels. In addition, we also analyzed the TAFIag-independent component of functional TAFI levels, with the aim to measure only the specific functional activity of TAFI, regardless of the TAFIag levels. We hope that our results will help to clarify the genetic factors that determine TAFI levels and, more importantly, that they will help to understand the genetic factors that affect the risk of cardiovascular disease.
Materials and methods

Subjects
Family members were recruited in Barcelona and were part of the GAIT (Genetic Analysis of Idiopathic Thrombophilia) Project. The sample included 21 families selected primarily for pedigree size, to maximize the power to detect genetic effects. To be included, a family had to have at least ten living individuals in three or more generations. Twelve families were selected through a proband with idiopathic thrombophilia, which was defined as multiple thrombotic events (at least one spontaneous), a single spontaneous episode of thrombosis with a first-degree relative also affected, or onset of thrombosis before age 45. Ten of the 12 probands had onset before 45 years, eight experienced multiple thromboses, and only two were ascertained because of a single episode of thrombosis with a relative also affected. The proband's thrombophilia was considered idiopathic because all known (during the recruitment period of 1995-1997) biological causes (e.g., antithrombin deficiency, Protein S and C deficiencies, activated protein C resistance, plasminogen deficiency, heparin cofactor II deficiency, Factor V Leiden, dysfibrogenemia, lupus anticoagulant, and antiphospholipid antibodies) of thrombophilia were excluded. These thrombophilic factors were also absent in all affected relatives. The remaining nine families were selected without regard to phenotype.
Subjects were interviewed by a physician to determine their health/reproductive history, current medications, including use of oral contraceptives, and smoking history. They were questioned about episodes of venous or arterial thrombosis; the age at which these events occurred, and the presence of potentially correlated disorders such as diabetes and lipid disease. The residence of each subject was determined to assess the contribution of shared environmental influences (such as diet) common to members of a household. All procedures were reviewed by the Institutional Review Board of the Hospital de la Santa Creu i Sant Pau. Adult subjects gave informed consent for themselves and for their minor children.
A total of 398 individuals were examined, with a mean of 19 individuals and 7 households per family. Subjects ranged in age from less than 1 year to 88 years with a mean of 37.7 and approximately equal numbers of males (46%) and females (54%). Of the individuals examined, 101 were founders (individuals whose parents are not in the pedigree) and 296 were non-founders. The number of households per pedigree ranged from 4 to 14 and the number of examined individuals per household ranged from 1 to 7, with a mean of 2.6. Most pedigrees contained three generations, with eight families having four generations and one having five.
Functional assays
Antigen determination of TAFI levels was performed by Zymutest TAFI, a commercial kit from Hyphen Biomed (Neuville-Sur-Oise, France). It is a Two-site ELISA method whose assay is designed with a murine monoclonal antibody specific for TAFI, and a goat polyclonal antibody labeled with Horse Radish Peroxidase (HRP) marker. Assay callibrator has defined concentration of TAFIag expressed as a percentage of normal pooled human plasma and exactly determined with 3 selected human plasma pools. Described inter-assay variation is between 5 and 10%. The inter-assay variation in our study was 7.9%.
TAFIf levels were measured following the method described by Mosnier et al. (1998) . It is based on the activation of the proenzyme TAFI in plasma with the complex Thrombin-Thrombomodulin and the measure of activated TAFI (TAFIa) with the hippuril-arginine substrate.
Genotypes
DNA was extracted using a standard method (Miller et al. 1988) . The genome scan has been described previously (Souto et al. 2000a, b) .
In addition, we genotyped two Single Nucleotide Polymorphisms (SNPs) in the TAFI structural gene (CPB2), one non-synonymous coding polymorphism located in exon 6 and causing an Ala147Thr variation (rs3742264) and one located in the 3 0 UTR region of CPB2 gene (rs940). Genotyping was performed by SNAPshoot technology using the ABIPRISM SNAPshootTM Multiplex kit and the ABIPRISM 3100Genetic Analyzer (Applied Biosystems) following the recommendations of the provider. We used the TCA AAG AAA TGC AGA ACA ATG forward and the ATG GCC TAT GAA CCA CAA GC reverse amplification primers for rs3742264, and the CCA GCA AGA CCA AAT CA forward and the ATT ACC GTG GAG CAA AC reverse primers for the amplification of rs940. Primers used for the minisequencing reaction were ATC CAT ATG GCA TTT TTG GCT G for rs3742264 and GAT GGC TAG TCA AAC GTC GAA A for rs 940.
The genotypic data were entered into a database and were analyzed for discrepancies (i.e., violations of Mendelian inheritance), using the INFER (PEDSYS) program (Dyke 1995). Discrepancies were checked for mistyping, and markers for discrepant individuals were either corrected or excluded from the analysis.
Linkage analysis
Standard oligogenic multipoint variance-component linkage methods, as implemented in the SOLAR software program, were used for the genome scan (Almasy and Blangero 1998). The goal of these analyses was to determine the contributions of genes, measured environmental factors specific to an individual, and environmental factors shared by members of a household to variation in hemostasis-related phenotypes. The phenotypic covariance among relatives was used to estimate the additive genetic and shared environmental components of variance.
The level of a trait, y, for individual i (yi) was modeled as a linear function as follows:
where l is the trait mean in males, xij is the jth covariate, and bj is its regression coefficient. Covariates included female sex, sex-specific age and age-squared, smoking, and for females, current use of oral contraceptives. Age-related covariates were scaled such that the regression coefficients represented the effect associated with a 10-year deviation from the mean age. Discrete covariates (female sex, smoking, and oral contraceptive use) were scaled so that the regression coefficients represent the effect of the presence of the covariate versus absence. The remaining variables in the above formula, gi, hi, and ei, represent the random deviations from l for individual i that are attributable to additive genetic, household, and residual error effects respectively. The residual error component includes true random error, measurement error and any non-additive genetic components. The effects of gi, hi, and ei are assumed to be uncorrelated with one another and normally distributed with mean zero and variances rg 2 , rh 2 and re 2 . The likelihood of the phenotypes of the family members is assumed to follow a multivariate normal distribution with a phenotypic covariance matrix that is a function of kinship between individuals and the additive genetic, household, and environmental variances.
This approach can be viewed intuitively as partitioning the observed phenotypic correlations among different classes of relatives in terms of underlying genetic and shared environmental factors. Once the expected means and covariance matrix of each pedigree are defined, the likelihood of a pedigree is evaluated using the multivariate normal density function and cumulated over pedigrees. Although we assume multivariate normality, this assumption is robust and consistent parameter estimates are obtained when the assumption is violated. Levels of TAFIag and TAFIf in the GAIT sample exhibited a kurtosis of 0.68 and 1.54 respectively. Recent statistical genetic theory demonstrated that this level of kurtosis does not affect the distribution of LOD scores and that the standard nominal P values for these LOD scores are appropriate (Blangero et al. 2000) . Marker maps for multipoint analyses were obtained from ABI-Prism and from the Marshfield Medical Research Organization. As 12 of the families were ascertained through thrombophilic probands, all analyses included an ascertainment correction achieved by conditioning the likelihood of these pedigrees on the likelihoods of their respective probands (Boehnke and Lange 1984). Genome-wide P values were calculated using the method of Feingold et al. (1993) .
Quantitative trait association analyses were performed using the measured genotype approach (Hopper and Mathews 1982) by testing for genotype-specific differences in the means of the trait while allowing for the non-independence among family members. To assess linkage and association simultaneously (Almasy and Blangero 2004) an extension of the variance component-based linkage tests was performed by simultaneously incorporating the genotype-specific means of the measured genotype test. These analyses were performed using the SOLAR software (Almasy and Blangero 1998).
Results
We used a variance component method to analyze TAFIag and TAFIf levels. We introduced sex, age, age squared, smoking behavior and contraceptive use as fixed effects in the linea model.
The TAFIag levels were significantly affected by age and age-squared, but that only accounted for 5% of the variability. Additive genetic effects (heritability) accounted for 40.9% and the remaining 59.1% represented environmental effects and error measurements.
For TAFIf levels, only smoking behavior was significant, accounting for 2% of the variability. Heritability represented 15.6% of the variance, household 22.7% and the remaining 61.6% was due to the error term.
The results of the multipoint linkage analysis over the 22 autosomal chromosomes for TAFIag levels are shown in Table 1 and in Fig. 1 . A suggestive linkage signal was found on Chromosome 13 (LOD = 2.28, P = 0.0006) in marker D13S156, the area where the structural gene coding for TAFI is located (Fig. 1) . However, other regions with LODs greater than two appeared on Chromosomes 5p and 7q. In silico search for candidate genes was performed in these chromosomal regions, although no obvious candidate genes were found (Table 1; Fig. 1) . Thus, our results suggest an oligogenic model of inheritance for TAFIag levels where several genes may be contributing to the TAFI variability.
In addition, we performed a linkage analysis intended to measure only the specific functional activity of TAFI, regardless of the TAFIag levels. We performed a multipoint linkage analysis of TAFIag-independent component of functional TAFI levels, i.e., considering the TAFIag levels as a controlled covariable in the analysis. There was clear evidence of linkage on chromosome region 19q13.3, near the marker D19S420 (LOD = 3.0, P = 0.0001) (Fig. 2) .
Finally, we genotyped two polymorphisms of CPB2, located at chromosomal positions 13:45525481 C/T (rs3742264) and 13:45546095 G/C (rs940). The former is located in exon 6 and causes an Ala147Thr variation, and the later is located in the 3 0 UTR region of the gene. These two polymorphisms have been associated repeatedly with variation in TAFI levels (de Bruijne et al. 2007; Frere et al. 2005; Juhan-Vague et al. 2002; Knoefler et al. 2003; Kostka et al. 2003; Morange et al. 2005) . Table 2 shows the differences in TAFIag and TAFIf levels for the different genotypes of these two SNPs. In our sample, the measured genotype analysis revealed a highly significant association of these two SNPs (P \ 0.0001 for both SNPs) and the TAFIag levels--altogether explained 32% of the variability in TAFIag levels--supporting the role of the CPB2 gene on the variation of TAFI levels. Specifically, rs3742264 explained 18% of the variability, and rs940 explained 28%. When we tested for a combined linkage-association analysis in this region with a model including the two polymorphisms as controlled covariables, the evidence of linkage dropped to 0.95. The fact that linkage did not drop to zero means that these two polymorphisms do not explain all of the linkage signal in this chromosomal region, and after controlling them as covariables, there is still an unexplained variability in the phenotype at this locus. Thus, it is likely that other yet undetermined polymorphic variants in CPB2 are causing the phenotypic variation in TAFIag levels.
Discussion
Activated TAFI down-regulates fibrinolysis by the removal of carboxi-terminal lysines from fibrin. Elimination of these lysines impaires the binding of plasminogen and its activators, resulting in a decreased generation rate of plasmin. Accordingly, many groups have tried to find an association between variation in TAFIag concentration or genotypes and thrombotic disorders (de Bruijne et al. 2007; Eichinger et al. 2004; Ladenvall et al. 2007; Montaner et al. 2003; Schroeder et al. 2002; van Tilburg et al. 2000) . Moreover, many allelic variants in the gene enconding TAFI (CPB2) have been genotyped in hopes of finding functional allelic variants that lead to an increased risk of thrombosis (Boffa et al. 2008; Brouwers et al. 2001; de Bruijne et al. 2007; Franco et al. 2001; Henry et al. 2001; Juhan-Vague et al. 2002; Morange et al. 2005) .
Some studies have estimated the heritability of the TAFIag. For example, twin studies in different European populations estimated TAFI heritabilities ranging from 71 to 82% for TAFI (Ariens et al. 2002; Bladbjerg et al. 2006; Peetz et al. 2004 ). However, classical twin studies tend to be biased because of similar environmental effects that lead to familiar correlations (Hopper 2002) .
Also, a recent study based on extended Mexican Americans families estimated the additive genetic heritability of TAFIag levels as 53% (Warren et al. 2006) . These studies found significant evidence of a QTL located near the locus of the TAFI coding gene. It is important to consider that heritability estimates cannot be compared between different populations and thus should be viewed qualitatively (Falconer 1996) . In our study, TAFIag showed a heritability of 0.41, which is similar to the estimate by the SAFHS Project based on a subset of healthy Mexican American families (Warren et al. 2006) . The heritability was much smaller than that obtained in the twin studies. In any case, the evidence is convincing that genes play a significant role in the variability of TAFIag levels. Therefore, there is a high probability that QTLs will be found that are responsible for this variability.
In contrast, TAFIf levels exhibited a low heritability (0.16) due, in part, to the significant household effect (0.25). The differences in heritability between TAFIag and TAFIf could be due in part to the different methodologies used in the measurement of the phenotypes.
From the Genome Wide Scan, we found a highly suggestive linkage signal on Chromosome 13, in the area where the structural gene coding for TAFI is located (LOD = 2.28, P = 0.0006). This result, in combination with the association of the two polymorphisms of the TAFI levels, confirms that some polymorphisms in the CPB2 gene are responsible for part of the variability of TAFIag levels. However, the evidence of linkage remained greater than zero (0.95) after including the two polymorphisms as covariates, which suggests that they cannot explain all of the evidence of linkage. Moreover, other signals greater than 2 (Table 1 ) suggest an oligogenic model of inheritance controlling the variability of TAFIag levels. Based on these results, we hypothesize that other genes, in addition to CPB2 on Chromosome 13, are responsible for the variability of TAFIag levels. Apart from two new suggestive signals on Chromosomes 5p and 7q, our results showed a strong significant linkage signal on Chromosome 19, near the marker D19S420 (LOD = 3.0, P = 0.0001) (Fig. 2) . These results are relevant, because they identifies a new QTL on Chromosome 19 involved in the specific functional activity of TAFI, regardless of the TAFIag levels.
The in silico search in these chromosomal regions did not reveal any obvious candidate genes on Chromosome 5. It is interesting that a member of the TFE3 subfamily of transcription factors is located within the linkage signal found on Chromosome 7. Finally, some biologically plausible candidate genes were found on Chromosome 19, such as the transcription factors (USF2) and other genes that may be important for the proper glycosilation of TAFI (G6PI).
Clearly, further studies are needed to fine-map these regions on Chromosomes 5, 7 and 19 to clearly elucidate the implication of these candidate genes. Ultimately, the search for new candidate genes affecting TAFI levels should continue in hopes of finding hallmarks for the risk of cardiovascular disease.
In conclusion, our results confirm the importance of CPB2 gene on TAFIag levels, and emphasize the need to study this gene in more depth. Moreover, we discovered a highly significant linkage signal on Chromosome 19 and 2 suggestive linkage signals on Chromosomes 5 and 7. Our hope is that our study will stimulate additional studies on this linkage signal that could represent potential new risk factors for thrombotic disease. Further analyses are needed to replicate these signals, and to confirm these provocative results that could be relevant in giving a clearer picture of the genetic determinants that are responsible for TAFI activity and its antigen levels.
